Current efforts to foster research on orphan diseases are focused largely on pharmaceutical treatments. Currently, there are roughly 770 FDA approved pharmaceutical treatments designated for orphan diseases. The number of treatments has greatly improved and it can largely be attributed to government efforts to foster research on orphan diseases. However, more can be done to bridge the gap between the number of available treatments, both pharmaceutical and non-pharmaceutical, and the number of different orphan diseases. These efforts should be supplemented by initiatives to bolster diffusion and commercialization of innovations made by the user-innovator community
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
Abstract Background The Orphan Drug Act was enacted in 1983 to encourage the development of drugs fo...
Through the combined efforts of agencies and organizations in the public and private sector, drugs h...
Current efforts to foster research on orphan diseases are focused largely on pharmaceutical treatmen...
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0....
Estimates of the frequencies of rare disorders vary from country to country; the global average defi...
significant changes within the pharmaceutical industry regarding resources expended to develop produ...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...
Abstract Background Orphan drug designations are a useful proxy to investigate trends in rare diseas...
Independent disease registries for pre-and post-approval of novel treatments for rare diseases are i...
Rare diseases remain a challenge for many of the countries in the world. The millions of people coll...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
A rare disease, or orphan disease, in the United States is a condition with a national prevalence of...
The Orphan Drug Act (ODA) [1], first enacted in the United States in 1983, was set up to encourage t...
ABSTRACT Rare diseases are a major public health problem and public health challenge. Orphan drugs ...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
Abstract Background The Orphan Drug Act was enacted in 1983 to encourage the development of drugs fo...
Through the combined efforts of agencies and organizations in the public and private sector, drugs h...
Current efforts to foster research on orphan diseases are focused largely on pharmaceutical treatmen...
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0....
Estimates of the frequencies of rare disorders vary from country to country; the global average defi...
significant changes within the pharmaceutical industry regarding resources expended to develop produ...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...
Abstract Background Orphan drug designations are a useful proxy to investigate trends in rare diseas...
Independent disease registries for pre-and post-approval of novel treatments for rare diseases are i...
Rare diseases remain a challenge for many of the countries in the world. The millions of people coll...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
A rare disease, or orphan disease, in the United States is a condition with a national prevalence of...
The Orphan Drug Act (ODA) [1], first enacted in the United States in 1983, was set up to encourage t...
ABSTRACT Rare diseases are a major public health problem and public health challenge. Orphan drugs ...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
Abstract Background The Orphan Drug Act was enacted in 1983 to encourage the development of drugs fo...
Through the combined efforts of agencies and organizations in the public and private sector, drugs h...